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ABSTRACT 
 
The mortality of cerebrovascular diseases is decreasing worldwide, but the 
prevalence is increasing and associated with a considerably poor quality of life. Moreover, 
diabetes mellitus damages the macrovasculature and microvasculature, increasing the 
incidence of cerebrovascular diseases several times. Rapid deterioration of brain injury 
has been shown in the presence of both diabetes and cerebral ischemia, but the 
mechanism is poorly understood. The treatment of cerebral infarction is extremely 
challenging because pharmacotherapy has limitations in terms of indication time-frame, 
and treatment options are limited. Therefore, primary prevention of cerebral infarction is 
important. We focused on oxidative stress and inflammation, which are commonly 
involved in both diabetic diseases and transient ischemic attack, and investigated food 
products for prophylaxis as alternatives of pharmacological agents, and reported the 
efficacy and safety of extracts from culture medium of Ganoderma lucidum mycelia 
(MAK). MAK has been consumed for many years as a food for specified health uses; it is 
derived from hot water-soluble extraction from the fragments of whole culture medium of 
Granoderma lucidum mycelia after a specific time period, and has been shown to 
suppress blood glucose elevation and has antioxidative activity. This review initially 
addresses the involvement of oxidative stress, inflammatory response, and high mobility 
group box 1 (HMGB1) as an etiology of brain injury deterioration in the combined 
condition of diabetes and transient ischemic attack, and thereafter the mechanism of 
brain-protection activity by MAK. 
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ABBREVIATIONS 
 
AA  ascorbic acid 
AGEs advanced glycation end products 
Bax  Bcl-2-associated X protein 
BBB  blood brain barrier 
CAT catalase 
CHOP C/EBP homologous protein 
COX-2 cyclooxygenase-2 
CRP C-reactive protein 
CSF cerebrospinal fluid 
DAPI 4',6-diamidino-2-phenylindole dihydrochloride 
DHA dehydroascorbic acid 
DHE dihydroethidium 
DM  diabetes mellitus 
DPPH 1,1-diphenyl-2-picrylhydrazyl 
dROMs derivatives of reactive oxygen metabolites 
Edaravone  1-phenyl-3-methyl-5-pyrazolone 
ER  endoplasmic reticulum 
ERK1/2 extracellular signal-regulated kinase 1/2, p44/42 MAPK  
  (Thr202/Tyr204) 
ETN etanercept 
GFAP glial fibrillary acidic protein 
GSH glutathione 
GLUT glucose transporter 
GPx glutathione peroxidase 
HIF  hypoxia inducible factor 
HO-1 hemeoxygenase-1  
Hsp70 heat shock protein 70 
HMGB1 high mobility group box 1 
Iba1 ionized calcium-binding adaptor molecule 1 
ICAM-1 intercellular adhesion molecule-1 
IDF  international diabetes federation 
IL-1β interleukin-1 beta 
IL-6 interleukin-6 
iNOS inducible nitric oxide synthase 
LPS lipopolysaccharide 
MAK water-soluble extract from culture medium of  
  Ganoderma lucidum mycelia 
MAPK mitogen-activated protein kinase 
MCAO middle cerebral artery occlusion 
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MCAO/Re middle cerebral artery occlusion/reperfusion 
MCP-1 monocyte chemotactic protein-1 
MMP-9 matrix metalloproteinase-9 
MPO myeloperoxidase 
MTT 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H- 
  tetrazolium bromide 
NADPH reduced nicotinamide adenine dinucleotide phosphate 
NeuN neuron specific nuclear protein 
NF-κB nuclear factor-kappa B 
NMDA N-methyl-D-aspartate 
nNOS neuronal nitric oxide synthase 
NO  nitric oxide 
non-DM non-diabetes mellitus 
O2  superoxide anion radical 
OH  hydroxyl radical 
ONOO peroxynitrite 
PC12 pheochromocytoma 12 
PKC protein kinase C 
p38 MAPK p38 mitogen-activated protein kinase 
QOL quality of life 
RAGE receptor for advanced glycation end products 
rHMGB1 recombinant HMGB1 
RNS reactive nitrogen species 
ROS reactive oxygen species 
RT-PCR real-time reverse transcription-polymerase chain reaction 
SOD superoxide dismutase 
STZ streptozotocin 
SVCT2 sodium-dependent vitamin C transporter 2 
TIA transient ischemic attack 
TLR toll-like receptor 
TNF-α tumor necrosis factor-alpha 
TNFR tumor necrosis factor receptor 
tPA  tissue-type plasminogen activator 
TTC 2,3,5-triphenyltetrazolium chloride 
TUNEL terminal deoxynucleotidyl transferase-mediated deoxyuridine   
  triphosphate-biotin nick end labelling 
XBP X-box binding protein 
 
 
1. INTRODUCTION 
 
Cerebrovascular diseases include intracerebral hemorrhage, subarachnoid hemorrhage 
and cerebral infarction, which are subdivided into atherothrombotic cerebral infarction, 
cerebral embolization, and lacunar infarction, accounting for a substantial proportion of all 
cerebrovascular disease [1]. On a worldwide basis, the mortality of cerebrovascular diseases 
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is decreasing, but the prevalence is increasing, and it has become a social problem because 
these diseases worsen the quality of life (QOL) in patients. The brain accounts for 2% of total 
body weight, but consumes 20% of total oxygen consumption. This characteristic may lead to 
the production of reactive oxygen species (ROS), which accounts for 2 to 5% of oxygen 
consumption. Moreover, the brain includes neuronal cells, glial cells, and endothelial cells. 
While glial cells and endothelium are relatively resistant to ischemia (hypoxia and 
hypoglycemia), neuronal cells and glial cells are extremely vulnerable. Transient ischemic 
attack (TIA) is defined as reversible brain hypoperfusion, whose signs and symptoms resolve 
within 24 hr, but may be associated with neuronal death even in transient ischemia because of 
the susceptibility to ischemia. Moreover, repetitive ischemia is more likely to result in 
cerebral infarction [2], and apoptosis of neurons because of oxidative stress at ischemia and 
reperfusion [3]. 
 The report in 2014 by the International Diabetes Federation (IDF) shows that diabetes 
affects 386.7 million people, 8.3% of the world adult population, and 4.90 million people died 
of diabetic complications. Chronic hyperglycemia increases oxidative stress such as ROS and 
reactive nitrogen species (RNS), and is a major risk factor for cerebral ischemia and 
atherosclerosis [4-7]. Previous studies in type 1 and 2 diabetic animal models have shown that 
concomitant diabetes worsens ischemic brain injury [8-10]. In the clinical setting, stroke is 
2/3-fold more likely to develop in patients with diabetes and is associated with poor outcome 
and increased mortality due to unexplained causes [11, 12]. 
 Previously, we focused on oxidative stress in both disorders of diabetes and transient 
ischemic attack; explored food products for the prophylaxis as alternatives of pharmacologic 
agents; and evaluated the efficacy and safety [8]. Investigation of several dozen natural 
compounds in foods with hypoglycemic and antioxidative activities resulted in identifying 
water-soluble extract from the culture medium of Ganoderma lucidum mycelia (MAK) after a 
specific time-period of culture. In addition, with the use of a model of transient cerebral 
ischemia in rats with streptozotocin (STZ)-induced diabetes mellitus (DM), cerebral injuries 
were shown to be enhanced as compared with non-diabetes mellitus (non-DM) rats, which 
was suppressed by orally administered MAK. Although apoptosis ascribed to oxidative stress 
and inflammatory processes is believed to play a major role, MAK has been shown to 
suppress necrosis as well as apoptosis, indicating that further studies are needed concerning 
the mechanism of activity because the brain-protective effect of MAK cannot be solely 
explained by common autoxidation. Therefore, we summarized the mechanism of activity of 
brain-protective MAK in addition to the already evaluated deteriorating processes in brain 
injuries. 
 
 
2. DIFFERENCE OF DAMAGE BETWEEN NON-DIABETIC  
AND DIABETIC CONDITION 
 
2.1. Involvement of Oxidative Stress 
 
In the cerebral cortex at the superacute phase of cerebral infarction, there is an ischemic 
core with severe damage, and a peri-infarction region with reversible mild-to-moderate injury 
(penumbra). In the ischemic core, electrotransport-system dysfunction, arachidonic acid 
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release associated with phospholipase A2 activation, and conversion from xanthine 
dehydrogenase to xanthine oxidase due to an unexplained cause occur, producing ROS [13]. 
By contrast, in endothelial cells in the penumbra, ischemia-activated neutrophilic reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase produces superoxides, which 
are associated with secondary deterioration due to endothelial dysfunction. Subsequently, in 
reperfusion, a large volume of blood enters the neuronal region in the state of ischemia-
associated ROS production. Therefore, oxygen delivery is increased; ROS are explosively 
produced, damaging the mitochondrial membrane. Simultaneously, in ischemic neuronal cell 
injury, release of glutamate, an excitatory amino acid, and elevation of intracellular calcium 
concentration occurred, leading to calmodulin activation and ROS production via neuronal 
nitric oxide synthase (nNOS). In addition, activated phospholipase A2 advances the 
arachidonic acid-cascade and increases ROS production, which are believed to be involved in 
various pathological conditions associated with reperfusion (Figure 1), glutamate-calcium 
hypothesis [14-16]). 
 
 
Figure 1. ROS generation after cerebral ischemia. 
Although the development of ischemia/reperfusion-driven oxidative stress and 
subsequent signal transduction has already been addressed, a diabetic state is reported to be 
associated with profound oxidative stress [17]. The production of oxidative stress in the 
diabetic state is divided into six steps: (1) Reducing sugar such as glucose nonenzymatically 
forms a Schiff base with an amino group followed by the production of stable Amadori 
compound through Amadori rearrangement, resulting in ROS production in an autooxidative 
process of the compound. (2) Irreversible dehydration and condensation are repeated, forming 
advanced glycation end products (AGEs), which binds to AGE receptors to stimulate ROS 
production, activate nuclear factor-kappa B (NF-κB) to stimulate various cytokines and 
growth factor, and induce an inflammatory response. Chronic hyperglycemic state including 
diabetes stimulates AGE production, the accumulation of which increases oxidative stress 
Naohiro Iwata, Mari Okazaki and Yasuhide Hibino 6 
[17-19]. (3) In hyperglycemia, the polyol pathway is activated, and glucose is converted to 
fructose. Fructose has a potent glycation effect compared to glucose. ROS is further produced, 
leading to increased intracellular oxidative stress and cellular dysfunction in association with 
NADPH consumption associated with polyol metabolism and the resultant decreased level of 
glutathione reductase (4). Activation of protein kinase C (PKC) increases endothelial NADPH 
oxidase activity, stimulating the production of oxidative stress. (5) AGEs reduce the activity 
of antioxidative enzymes including superoxide dismutase (SOD) and glutathione peroxidase 
(GPx) and reduce the levels of low-molecular-weight antioxidants including vitamins C and E. 
(6) The interaction between superoxide anion radical (
.
 O2
-
) and nitric oxide (NO) leads to the 
production of peroxynitrite (ONOO
-
) resulting in protein nitration. In a diabetic state, those 
phenomena are enhanced to induce oxidative stress-driven atherosclerosis and micro- and 
macro-angiopathy. ROS including 
.
 O2
-
 , hydrogen superoxide (H2O2) and hydroxyl radical 
(OH) induces DNA damage, lipid peroxidation, and protein degeneration associated with 
adverse effects to the organism. As evidence suggests that ROS is involved in diabetes and 
many other disorders [12, 20], the decrement of oxidative stress in order to prevent and 
alleviate diseases has gained attention. 
Iwata et al. assessed the level of in vivo oxidative stress with the use of circulating levels 
of hydroxyperoxide as the marker in SD rats as a model of type 1 diabetes mellitus (DM) with 
a blood sugar level of 543.2 ± 42.6 mg/dL in which a single administration of streptozotocin 
had been performed [8]. The levels of derivatives of reactive oxygen metabolites (dROMs) 
were expressed in CARR units (1U-CARR corresponds to 0.08 mg hydrogen 
peroxide/100mL). Oxidative stress was significantly elevated at the level of 252.8 ± 32.9 
U·CARR in the diabetic group as compared with 131.0 ± 7.0 U·CARR in the non-diabetic 
group (blood sugar level of 123.5 ± 13.5 mg/dL), for a roughly two-fold increase. Moreover, 
antioxidative potential was significantly lowered at a level of 1475.7 ± 67.1 μmol/L in the 
DM group as compared with in the non-DM group (1875.4 ± 156.1 μmol/L). Lipid peroxide-
level in the brain tissue was significantly elevated in the DM group by a factor of 1.3 to 2.0 as 
compared with that in the non-DM group, indicating the brain tissue under oxidative stress in 
DM, reflecting the oxidative stress level and antioxidative potential. 
To maintain biological homeostasis, intrinsic and extrinsic removal mechanisms are 
essential against various toxicities of ROS. In terms of intrinsic ROS removal mechanisms, 
antioxidant enzymes including SOD, catalase (CAT), and GPx are involved. Therefore, the 
activity of antioxidative enzymes was measured: the activities of SOD, CAT, and GPx were 
significantly lowered in almost all brain regions (cortex, striatum plus hippocampus, 
cerebellum, and brain stem) [21]. 
By contrast, an extrinsic ROS removal system such as ingestion of antioxidative 
compounds including vitamin C is believed to be crucial [22-25]. Evidence suggests that, in 
DM, reduced circulating levels of vitamins C and E lowers in vivo antioxidative potential, and 
induces the production of 
.
 O2
-
 and H2O2, augmenting nonenzymatic glycation of proteins [26]. 
Furthermore, as glycation leads to ROS production, reduced activity of antioxidative enzymes 
may be ascribed to increased production of ROS including 
.
 O2
-
 and H2O2. These results 
suggest that oxidative stress is always present in a diabetic state even if otherwise normal, and 
that oxidative stress is present locally in the brain and systemically because of reduced 
activity of antioxidative enzymes and elevated levels of peroxidized lipids.  
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2.2. Altered Gene Expression in Ischemic Brain Injury 
 
In ischemic brain injury, infarctional lesions are induced immediately after the occlusion 
of brain vessels, and extends from the ischemic core to the penumbra. Activated microglia 
induce the production of inflammatory cytokines such as interleukin-1 beta (IL-1β) and 
chemokines such as monocyte chemoattractant protein (MCP-1) in the progression of 
infarction [27]. In addition, astrocytes are activated, leading to increased production and 
secretion of S100B, which interacts with neurons, microglias, and astrocytes, resulting in 
increased expression of inflammatory factors and exacerbation [28]. As recent evidence 
suggests that inflammatory processes including C-reactive protein (CRP), an inflammatory 
marker, and interleukin-6 (IL-6) may be closely associated with atherosclerosis and 
arteriolosclerosis, which may cause cerebral infarction, clarification and control of the 
progression of inflammation are believed to be effective to protect the brain. Moreover, after 
cerebral ischemia, various reactions including apoptosis, stress against endoplasmic reticulum 
(ER), and protective factor production develop in addition to inflammation. Especially in a 
diabetic state, the above-mentioned and other factors are involved, complicating the 
deterioration. Iwata et al. collected reperfusion (Re)-treated brain specimens over time after 
the middle cerebral artery occlusion (MCAO) to evaluate brain injury and inferred the 
mechanism of progression and exacerbation by means of genome-wide expression analyses of 
brain tissue in nondiabetic and diabetic conditions. Coronal sections of 2 mm-thickness were 
obtained from removed brains after 1, 3, 6, 12, 24, 48, and 72 hr in the non-DM group, and 
after 0.5, 1, 3, 6, 12, and 24 hr, and stained with 2,3,5-triphenyltetrazolium chloride (TTC) to 
measure infarctional volume and cerebral edema. In the non-DM group, infarctional lesions 
started to develop 12 hr after ischemia/reperfusion, whose volume gradually expanded and 
reached approximately 50% of ipsilateral hemisphere at 48 hr and later (Figure 2). By 
contrast, edema progression was profound in the DM group as compared with in the non-DM 
group [29]. Thus, brain injury associated with ischemia/reperfusion developed earlier in a 
diabetic- than in a non-diabetic condition, suggesting that the progression may hamper 
survival 24 hr after reperfusion or later. Moreover, we exploited a DNA microarray method 
for genome wide expression analyses against a total of 27342 genes to determine the 
mechanism of brain-injury progression, and identified genes whose expression increased or 
decreased by a factor of 2 as compared with that of the non-DM sham surgery group. In the 
non-DM group, the expression changed in 64 genes at 1 hr after ischemia/reperfusion, 28 at 3 
hr, and 145 at 12 hr. In the DM group, the change occurred in 82 genes at 1 hr, 215 at 3 hr, 
and 368 at 12 hr: in the brain tissue of the DM group, as compared with those of the non-DM 
group, the greater number of genes altered the expression time-dependently. In particular, 
gene expression associated with inflammation, oxidative stress, and apoptotic pathway 
increased over time, which occurred profoundly early 1 hr after reperfusion in the diabetic 
state (data not shown). Subsequently, the time course of inflammation-related gene 
expression was investigated up to 72 hr by means of real-time reverse transcription-
polymerase chain reaction (RT-PCR) on the basis of results of DNA microarray analyses. The 
penumbra of the cerebral cortex increased the expression of tumor necrosis factor-alpha 
(TNF-α) and IL-1β by a factor of 2.0 and 5.6, respectively, which was already profound in the 
early phase after ischemia/reperfusion. By contrast, the expression of IL-6, cyclooxygenase-2 
(COX-2) and matrix metalloproteinase-9 (MMP-9) increased later over time following 
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ischemia/reperfusion (MCAO/Re) and the gene expression of the upstream mediators 
including TNF-α and IL-1β in the DM rat group as compared with in the non-DM rat group. 
 
 
Figure 2. Brain infarct and edema in non-DM and DM ischemic rats detected by TTC staining. 
(A) Images of representative coronal brain sections from non-DM (non-type 1 diabetes 
mellitus) rats and DM (type 1 diabetes mellitus) rats stained by TTC (2,3,5-
triphenyltetrazolium chloride) at various time points after MCAO (middle cerebral artery 
occlusion)/Re (reperfusion) showing viable (red) and dead (pale pink) tissues. Scale bar = 5 
mm. (B) Infarct volume in the ischemic hemispheres of non-DM and DM rats after 
MCAO/Re, assessed by TTC staining. The infarct volume was calculated as follows: infarct 
volume (%) = [LV - (RV-MV)]/LV×100 (MV: infarct volume, RV: right hemisphere volume, 
LV: left hemisphere volume). Scale bar = 5 mm. N.D.: not determined. Data are means ± S.D. 
(n = 3-4 per time point). *P < 0.01 vs. corresponding values for the non-DM.  
The brain is a visceral organ where the blood-brain barrier (BBB) strictly controls 
molecular transition from circulating blood to cerebrospinal fluid. Transient brain ischemia is 
associated with an increased level of cytokines such as IL-6 in circulating blood and activated 
MMP-9 and subsequent BBB disruption, leading to cytokine-influx to brain tissue and more 
extensive damage [30]. Cerebral edema is divided into cytotoxic edema characterized by 
intracellular water retention and vasogenic edema characterized by BBB disruption. However, 
the distinction is equivocal in the clinical setting. Edema is also involved in the exacerbation 
of cerebral infarction associated with ischemia/reperfusion. It is believed in the rat model of 
cerebral edema that at an early stage, foot-process edema of astrocytes is followed by 
detachment from endothelial cells with transition to vasogenic edema due to BBB disruption 
[31]. As mentioned above, on the basis of expression analysis of MMP-9 gene over time, 
BBB disruption is considered to be ascribed to additionally increased level of MMP-9, which 
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was significantly increased in the sham group of DM, with the ischemic procedure. Therefore, 
permeability was assessed as the function of BBB with the use of Evans blue staining. The 
Evans blue binds circulating proteins and become high-molecular compounds, which 
normally cannot cross the BBB. While the leakage into cerebral tissue was observed 24 hr 
after ischemia/reperfusion in the non-DM group, it is earlier observed 1 hr after reperfusion in 
the diabetic status, indicating that BBB is disrupted in the earlier stage (Figure 3). The 
evidence indicates that ischemic brain injury may develop earlier in the DM group than in the 
non-DM group and that the injury pattern reflects the altered gene-expression of 
inflammatory mediators: i.e., in a diabetic state, excessive oxidative stress is constantly 
present even when otherwise normal; and in brain tissue, peroxidized lipid accumulates as 
antioxidative enzymes are inactivated. Moreover, in the condition of various oxidative stress-
induced inflammatory processes, further ischemia/reperfusion-stimulated excessive 
inflammation and cell death may develop in a short time-frame, which causes BBB disruption 
and further deterioration.  
 
 
Figure 3. Blood-brain barrier permeability by Evans blue stain. 
Representative coronal brain sections of DM and non-DM rats stained by Evans blue at 1, 
3 and 24 hr after MCAO/Re. Scale bar: 5 mm. sham: sham-operated rats which are meaning 
normal rats operated as a control.  
 
 
2.3. Involvement of HMGB1 Pathway in Ischemic Brain Disorder 
 
The expression of many genes and proteins controls cytoprotection and cell death in brain 
cells of ischemic disorder. Heat shock protein 70 (Hsp70), which is a stress protein and a 
penumbra marker, is expressed in neurons, inducing modification and ubiquitination of 
denatured proteins to protect the brain. Moreover, evidence suggests that Hsp70 [32] and αB-
crystalline of an effector of unfolded protein response [33] is expressed in astrocytes along 
with hemeoxygenase-1 (HO-1) [34] in microglias and some neurons, protecting brain. By 
contrast, apoptosis-related factors including Bcl-2-associated X protein (Bax) and caspase, 
and endoplasmic reticulum-stress factors including X-box binding protein (XBP), and C/EBP 
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homologous protein (CHOP) are expressed. The brain is an organ composed of various cells 
including neurons and glial cells such as astrocytes, microglias and oligodendrocytes, where 
each cell has specific expression of genes and proteins. This fact hampers clarification of the 
mechanism in brain injury. We focused on inflammatory processes after ischemic brain injury 
among a plethora of pathways associated the transient cerebral ischemia; and compared the 
changes of high mobility group box 1 (HMGB1), which have recently gained attention as an 
inducer of this pathway, between non-diabetic and diabetic groups [29]. 
 
 
Figure 4. Pathways of HMGB1 secretion. 
HMGB1 was found as a DNA-binding non-histone protein that plays a crucial role in 
maintaining DNA conformation. Initially, many studies focused on the involvement in 
transcriptional regulation, repair, and inflammation [35]. However, in 1999, the utility was 
intensively studied as a severity marker of sepsis reflecting life-threatening possibilities and 
as a management marker [36]. The amino acid-sequence is conserved among biological 
species with a difference of only two residues among 215 amino acid residues between 
rodents and human beings [37]. All of HMGB1 are usually present within the nucleus. 
However, it is released passively from the nucleus via cytoplasmic cytosol to the extracellular 
space in activated monocytes and macrophages [36, 38], maturated dendritic cells [39], 
endothelial cells [40], and necrotic cells [41]. Figure 4 shows that extracellular released 
HMGB1 activates NF-κB by interaction with receptors for advanced glycation end products 
(RAGE), toll-like receptor-2 and TLR4 on the cytoplasmic membrane of various cells [37, 
41]. An experiment using glial cells from mice revealed that administered HMGB1 induced 
HMGB1
Activated cells
Necrotic cells
Lipopolysaccharide（LPS）
Interferon- （IFN-）
IL-1
TNF-
HMGB1
HMGB1
acetylation
Vesicle import
HMGB1
Secretion
HMGB1
HMGB1
Ischemia 
(injury)
HMGB1
RAGE
Ras Rac1
p38
ERK1/2
ILL ILL
NEMO
NF-B
IB
IB
TLR2/4
PI3K
CDC42
Rac1
MyD88
TIRAP
IRAKs
TRAF6
TAK1
TAB2
Akt
CDC42
NF-B
Mechanism of Exacerbation of Neuronal Damage After Cerebral Ischemia 11 
the expression of inflammatory factors including TNF-α, inducible nitrite synthase (iNOS), 
and COX-2 [42], indicating that HMGB1 itself is proinflammatory and cytotoxic factor: i.e., 
extracellular released HMGB1 affects directly adjacent cells. It is currently believed that 
HMGB1 is a key mediator in acute inflammation including sepsis, acute lung injury, trauma, 
postsurgical condition, disseminated intravascular coagulation, and ischemia/reperfusion as 
well as in a plethora of conditions including chronic inflammation such as rheumatoid 
arthritis, atherosclerosis, and the growth and invasion of malignant tumors [43-45]. Evidence 
suggests that HMGB1 is closely associated with the inflammatory process after cerebral 
ischemia. However, the role of HMGB1 receptors and the mechanism of brain-damage 
development remains unclear.  
 
 
Figure 5. Cell death induced by HMGB1 in PC12 cells. 
Therefore, Iwata et al. assessed the effect of HMGB1 on cellular injury after transient 
cerebral ischemia [29]. As mentioned above, HMGB1, a nuclear protein, is released into the 
extracellular space, and has itself a deleterious effect. For the replication of that phenomenon 
in cultured cells, a nerve growth factor was administered to rat adrenal pheochromocytoma-
derived PC12 cells in order to differentiate to neuron-like cells. HMGB1 was administered to 
those cells, and cell survival was determined at 24 hr by means of MTT assay. The survival 
was decreased as increasing HMGB1 concentration (Figure 5). Moreover all of H2O2 
(oxidative stressor), TNF-α, and exogenous HMGB1 released intracellular HMGB1 from 
nucleus via cytoplasm into the extracellular space, which was compatible with previous trials 
(Figure 6). Intranuclear HMGB1 is released actively from activated macrophages and 
monocytes, and passively from necrotic cells by the stimulation of TNF-α,  
IL-1β, and lipopolysaccharide (LPS), which are produced in the early phase of inflammation. 
Acetylation [46] and phosphorylation [47] control the translocation to the nucleus, while 
secretory lysosome controls the secretion to extracellular space. In addition, it has been 
reported that HMGB1 is not released from apoptotic cells, but from necrotic cells [48]. In 
recent years, HMGB1 has been believed to be a mediator in ischemic brain injury [49] as well 
as in intrapulmonary bleeding of acute lung injury [50], and liver injury after hepatic 
ischemia/reperfusion [51].  
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PC12 cell (1×10
5
 cells/well) were incubated with rHMGB1 (recombinant HMGB1) for 
24 hr and the cell survival was determined by MTT assay. The open column shows the non-
DM group and the closed column shows the DM group. Data are means ± S.D. (n = 6). *P < 
0.01 for statistical significance compared to the control. 
 
 
Figure 6. Immunohistochemical staining of HMGB1 in PC12 cells. 
PC12 cells were treated with H2O2, TNF- and rHMGB1, and then HMGB1 was stained 
with anti-HMGB1 antibody (red) and DAPI (blue). Arrowhead indicates, HMGB1 in 
cytoplasm. 
As ischemia/reperfusion precipitates cell death in the diabetic rat brain, the association 
between locoregional variation of necrotic cell-released HMGB1 and ischemic brain injury 
over time was evaluated. Initially, expression of the HMGB1 gene in the cortical penumbra 
after the brain ischemic procedure was compared between both groups. There was no 
significant difference, suggesting that diabetic state and ischemia/reperfusion do not affect 
HMGB1-gene expression. Thereafter, coronary-section specimens of frozen brain tissue were 
stained for HMGB1 and nucleus with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI). 
In addition, triple immunostaining was performed against neurons (neuron specific nuclear 
protein: NeuN), astrocytes (glial fibrillary acidic protein: GFAP), and microglias (ionized 
calcium-binding adaptor molecule 1: Iba1). HMGB1 was gradually translocated from the 
nucleus to the cytoplasm 6 to 12 hr after ischemia/reperfusion in the cerebrocortical HMGB1-
enriched cells of the non-DM rat sham group, which is in accordance with findings of Qui’s 
study [49] indicating that neurons are the major source of HMGB1 in early ischemic brain 
injury. By contrast, the translocation of HGMB1 to cytoplasm had already occurred before 
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ischemia/reperfusion and been excreted extracellularly from all cells of the ischemic core 
after 1 hr in the diabetic rat group [29].  
Evidence suggests that the serum level of HMGB1 is elevated in patients with cerebral 
infarction as a mediator of ischemic brain injury [52]. Therefore, Iwata et al. assessed the 
variation over time in the cerebrospinal fluid (CSF) and in the plasma. There was no 
difference in HMGB1 level between the non-DM sham group and the DM sham group of rats. 
While the HMGB1 level markedly increased 1 hr after reperfusion in the DM rat, the level 
gradually increased up to 12 hr after reperfusion. The variation of HMGB1 in plasma level 
over time is similar to that in CSF. The evidence suggests that after transient cerebral 
ischemia HMGB1 in cerebral neuron translocates from the nucleus to the cytoplasm and is 
immediately excreted into the extracellular space, contributing to early inflammation as an 
upstream initiator locally in the brain and systemically [29].  
Previous studies have suggested that the proinflammatory effect of HMGB1 is mild alone, 
but is enhanced markedly in the concomitant presence of other factors including IL-1 and 
LPS [53, 54]. The HMGB1 releases due to TNF-α and IL-1β, in addition to the release from 
necrotic cells, are considered to constitute a major pathway. Therefore, we assessed the 
expression of proinflammatory cytokines after ischemia/reperfusion. The gene expression of 
IL-1β and TNF-α was significantly increased in the sham group of diabetic rats by a factor of 
5.6 and 2.0, respectively as compared with in the non-diabetic rat group. The expression of 
MMP-9 was increased by a factor of 2.6 in the sham (control) rat group in the diabetic rat, 
while the incremental pattern did not differ between the non-DM and DM groups after 
cerebral ischemia/reperfusion. Other studies have suggested that induced MMP-9 is involved 
in the disruption of the BBB as a deleterious factor in cerebral infarction [55, 56]. Taking 
these findings together, we conclude that the expression of TNF-α and IL-1β stimulates 
HMGB1 release in the diabetic state, which itself induces the production TNF-α and IL-1β, 
forming an inflammation-amplifying vicious cycle. 
The receptor for advanced glycation end products (RAGE) is a member of the 
immunoglobulin superfamily expressed on neurons, glial cells and endothelia in the brain 
[57-60]. RAGE-ligands include AGEs, β-amyloids, and S-100 proteins in addition to 
HMGB1 [61]. In particular, HMGB1 has a seven-fold affinity as compared with AGE, which 
was initially found as a ligand to HMGB1 in an integral study of rat-derived cultured neurons 
with the use of [
125
I]-HMGB1 [62]. Moreover, interaction of HMGB1 with RAGE on cell 
membranes leads to NF-κB activation [63] via phosphorylation of mitogen-activated protein 
kinase concerning intracellular signal transduction in macrophages [64] and neutrophils [65]. 
In terms of ischemia/reperfusion-associated injury, the presence of receptors is crucial for 
evaluation of the inflammatory process in which HMGB1, as a receptor, activates 
intracellular signal transduction. Intriguingly, the volume of ischemia/reperfusion-caused 
infarcts has been shown to decline in RAGE-knock-out mice and with soluble RAGE [66], 
indicating that increased RAGE expression adversely affects ischemic cerebral injury. 
Therefore, the magnitude of RAGE expression is determined, which gradually increased up to 
12 hr after reperfusion in the non-DM rats, while the expression is increased before 
reperfusion in the DM rats of the sham group, which persisted stably up to 12 hr after 
reperfusion. RAGE expression is induced by hypoxia-inducible factor-1 (HIF-1) [67, 68]. 
TNF is also known as a RAGE inducer. Mitochondrial electron transport system-derived ROS 
augments RAGE expression in hyperglycemia [69]. RAGE expression is increased, which 
could be mitigated with antioxidants in the brain of diabetic animal models [70], suggesting 
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that lowered oxidative stress suppressed the expression. In our study, an increased level of 
ROS and TNF was observed, suggesting that those effects influence increased RAGE 
expression, and that the further expression caused by ischemia/reperfusion contributes to 
worsening ischemic cerebral injury.  
Toll-like receptor (TLR), which is considered another receptor of HMGB1, is a one-
transmembrane receptor; plays an important role in the innate immune system; and recognizes 
components of many pathogens including bacteria, viruses and fungi and conducts signal 
transduction. Evidence suggests that the signal transduction into cells is involved in NF-κB-
induced inflammatory process through MAPK activation along with RAGE. Recent studies 
have demonstrated that HMGB1 increases MMP-9 expression through toll-like receptor 4 
(TLR4) after cerebral ischemia in neurons and astrocyte, resulting in BBB disruption and 
cerebral edema [55, 71]. An elevated level of MMP-9 is caused by HMGB1 independently of 
TNF-α [71], and HMGB1-TLR signal transduction pathway is closely associated with the 
inflammatory process [49, 72]. Our unpublished data reveal that TLR4 expression does not 
change up to 12 hr after reperfusion in non-DM rats, while the expression peaks after 3 hr in a 
diabetic state, followed by a decrease after 12 hr. The evidence suggests that extracellular 
release of HMGB1 and increased number of receptors may stimulate intracellular signal 
transduction. Furthermore, phosphorylation of ERK1/2 and p38, and translocation of NF-κB 
into the nucleus were slightly enhanced up to 12 hr after reperfusion in cerebrocortical 
penumbra of the non-DM group, whereas the phosphorylation of ERK1/2 was prominent 3 hr 
after reperfusion, and present at 12 hr. Phosphorylation of p38 and intranuclear translocation 
of NF-κB were already present in the sham group, and ischemic procedure resulted in its 
augmentation. Akt phosphorylation peaked 3 hr after reperfusion in both groups, although the 
phosphorylation was increased in the sham group of DM. The expression of COX, which is 
downstream of signal transduction, was markedly increased 3 to 12 hr after reperfusion only 
in the DM group.  
Until now, HMGB1-targeted treatment strategies have been advanced, one of which is 
ethyl pyruvate. Treatment with this compound downregulates expression of HMGB1 in 
cardiac ischemia/reperfusion, and suppresses activation of HMGB1/TLR4/NF-κB pathway, 
exerting a cerebroprotective effect in traumatic brain injury [73, 74]. Intravenous 
administration of nafamostat mesilate suppresses TNF-α expression, which indirectly 
suppresses HMGB1 expression and mitigates lung injury in an endotoxic shock model [75]. 
In addition, anti-HMGB1 antibody has a BBB-protective effect and decreases infarct volume 
[76, 77]. HMGB1-target therapies are expected to be established. 
Recent studies using human endothelia have suggested that hyperglycemia-induced ROS 
increases the expression of HMGB1 in rats [69, 78]. We observed increase of in vivo 
oxidative stress and decreased antioxidative capacity; and increased level of lipid peroxide 
associated with decreased level of antioxidative enzymatic activity in brain tissue, confirming 
that that oxidative stress is augmented in the brain [8]. One possible explanation is that 
augmented oxidative stress in the diabetic state markedly affects the HMGB1/RAGE pathway, 
resulting in worsened ischemic brain injury. Taking these findings together, as shown in 
Figure 7, ROS production is increased in the diabetic state as compared with in the non-
diabetic state; ischemia/reperfusion early alters intracellular distribution of HMGB1; excreted 
abundant HMGB1 interacted with receptors of RAGE and TLR2/4, activates intracellular 
signal transduction, and inducing inflammation and cell death. In conclusion, increased 
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extracellular HMGB1 is a major deleterious factor of ischemic cerebral injury, and induces 
severe inflammation and cell death in the penumbra as well as in the ischemic core. 
 
 
Figure 7. HMGB1 secretion and signal transduction pathways. 
HMGB1 can be released into the extracellular space actively from macrophages and 
monocytes or passively from necrotic cells. Extracellular HMGB1 interacts with different 
receptors such as RAGE or TLR2/4 and promotes inflammatory responses leading to 
mitogen-activated protein kinase (MAPK) and NF-B activation. A diabetic state induces 
pro-inflammatory cytokines in the brain, conceivably via hyperglycemia and/or oxidative 
stress, accelerating intracellular translocation and the release of HMGB1 from neuronal cells 
after ischemic injury. Increase in extracellular HMGB1 may further induce the inflammatory 
response and cellular necrosis in the ischemic penumbra, leading to aggravation of ischemic 
injury in a diabetic state. 
 
 
2.4. Involvement of Cytokines 
 
In gene expression analyses with the use of the above-mentioned DNA microarray 
methods, inflammation-associated gene expression was elevated early in ischemia, strongly 
suggesting the involvement of inflammation in acute cerebral ischemia. With regard to 
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intracellular localization of HMGB1, which is an intracellular protein and an inflammatory 
mediator, intracellular distribution of HMGB1 profoundly changed in the DM group, which 
suggests activation of downstream signal transduction. As, until now, previous studies have 
suggested that cytokines including TNF-α and IL-1β stimulate the release of HMGB1 from 
activated cells and propel inflammation, an in-depth understanding concerning cytokine-
expression in ischemic brain injury is crucial. 
Therefore, the expression of IL-1β was determined in cerebrocortical penumbra over time 
after ischemia/reperfusion. The expression was increased 24 hr after the ischemic procedure. 
By contrast, the expression was significantly increased in the DM sham group by a factor of 
3.5 as compared with in the non-DM sham group; and profoundly increased 3 hr after 
reperfusion by a factor of 25 (Figure 8), revised from reference [79]. The TNF-α expression 
was increased 24 hr after the ischemic procedure by a factor of 5 as compared with the non-
DM sham rat group. By contrast, the expression was increased by a factor of 1.4 in the DM 
sham rat group as compared with in the non-DM sham rat group; and increased profoundly by 
a factor of 11 after reperfusion as compared with in the non-DM rat group, whose level 
remained elevated 24 hr after reperfusion. Moreover, the expression of proinflammatory 
factors including COX-2 and iNOS was determined over time: COX-2 is a relatively 
downstream inflammatory mediator and the expression is controlled by transcription factors 
such as NF-κB. COX-2 expression was markedly increased in each DM rat group: i.e., in the 
sham rat groups (non-DM; 0.08 ± 0.02, DM; 0.13 ± 0.08); and at 3 hr (non-DM; 0.12 ± 0.01, 
DM; 0.50 ± 0.04) and at 24 hr (non-DM; 0.27 ± 0.03, DM; 0.36 ± 0.05) after reperfusion. 
Similarly, the expression of iNOS was increased over time with MCAO/Re procedure in the 
non-DM and DM groups, and the increment was greater in the sham rat group, and 3 and 24 
hr after reperfusion in the DM rats [79]. Leukocyte infiltration to inflammatory sites is 
controlled by cell adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1). 
The expression is rapidly enhanced via proinflammatory cytokines in inflammation, leading 
to recruitment to endothelium and extraversion of leukocytes. Therefore, the expression of 
ICAM-1 and a leukocyte infiltration marker, myeloperoxidase (MPO) was determined. The 
ICAM-1 expression increased over time after the ischemia/reperfusion procedure in both of 
nondiabetic and diabetic states; and the increment was also greater in the DM sham rat group 
(non-DM; 0.02 ± 0.03, DM; 0.12 ± 0.02) and at 24 hr after reperfusion (non-DM; 0.29 ± 0.07, 
DM; 0.94 ± 0.24). In addition, the MPO expression gradually increased, whose activity was 
greater 24 hr after reperfusion in the diabetic state than in the nondiabetic state [79]. The 
evidence suggests that because cerebral cortex is more likely to provoke inflammation in the 
diabetic state than in the nondiabetic state, ischemia/reperfusion precipitates dramatic 
expression of proinflammatory mediators in the penumbra: i.e., the constellation of reactions 
is involved in enlargement of cerebral infarct lesions, strongly suggesting the importance of 
inflammation-control for cerebral protection. 
As inflammation is involved in the early stage of ischemic cerebral injury and diabetes, 
the therapeutic effect of the biological product etanercept (ETN), which captures and 
neutralizes free TNF-α, was assessed in the ischemia/reperfusion procedure [80]. ETN 
administered after ischemia/reperfusion was ineffective at any dose in both non-DM and DM 
rats. However, the single dosage after ischemia or before the ischemic procedure had a 
cerebroprotective effect in the non-DM group; and ETN was effective when the 
administration occurred repetitively immediately after the development of diabetes, 
suggesting that suppression of sole cytokines cannot lead to a meaningful therapeutic effect 
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because the inflammatory process develops abruptly in diabetes and after ischemia. A drug is 
not ordinarily administered as therapeutic intervention before the occurrence of cerebral 
ischemia. However, diabetes is a risk factor for cerebral infarction. Preceding inflammation 
may markedly worsen disability caused by cerebral ischemia. Therefore, reduction of early 
inflammation as a prophylaxis may lessen disability in cerebral infarction. Whether disability 
caused by cerebral infarction can be alleviated with daily ingested food or its constituents as a 
pharmaceutical agent was investigated.  
 
 
Figure 8. Expression of IL-1 in the penumbral cortex after MCAO/Re in non-DM and DM rat brains. 
Representative photographs of IL-1 immunostaining (red fluorescence) and nuclei by 
TO-PRO-3 (blue fluorescence) in the cortex coronal sections of the non-DM and DM rats (A). 
Quantitative analysis of IL-1 fluorescence intensity in the cortex (B). Scale bar: 100 m. 
Data are means ± S.D. (n = 3). **P < 0.01 for statistical significance compared to the non-
DM + H2O rat group. 
 
 
3. IMPROVEMENT OF ISCHEMIC CEREBRAL INJURY  
WITH ANTIOXIDATIVE FOOD OR CONSTITUENTS 
 
3.1. Evaluation of Cerebroprotective Effect of Ascorbic Acid 
 
There are two strategies of improving blood flow therapy and brain protective therapy 
toward cerebral infarction acute treatment. The latter strategy focuses on the protection of 
both brain cells and endothelium. Oxidative stress plays a critical role in the acute phase. Its 
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modulation has been considered important, and many agents have been developed. Among 
others, edaravone (1-phenyl-3-methyl-5-pyrazolone), which suppresses oxidative stresses 
such as ・OH radicals, and the damage of free radical-susceptible membrane lipids has been 
shown to be effective in the clinical setting in Japan. As edaravone reduces hemorrhage size 
after the administration of a thrombolytic agent, edaravone, tissue-type plasminogen activator 
(tPA), and a combination of those agents are believed to be beneficial. Moreover, in the 
Japanese guidelines for the management of stroke in 2009, edaravone is classified into grade 
B (recommended to perform), and suppression of oxidative stress is shown to be effective to 
protect the brain [81]. As above-mentioned, substantial oxidative stress occurred after 
ischemia/reperfusion, which is greater in DM rats than in non-DM rats; and the each cerebral 
region is under prominent oxidative stress. Therefore, a typical antioxidative food or its 
constituent, L-ascorbic acid (AA, vitamin C) was investigated concerning cerebroprotective 
effect after reperfusion. 
AA is a major antioxidative vitamin. Through the transporter, ingested AA is transferred 
and stored in body tissues, especially in the adrenal grands, ocular lenses, and brain in higher 
concentrations, exerting physiological functions. Although AA and other antioxidants are 
present in the blood circulation, AA especially promptly captures and eliminates excessive 
ROS [82]. Rats and mice can synthesize AA from D-glucose, and rats synthesize in the liver 
at a level of 150 mg per kilogram of body weight per day. By contrast, primates such as 
human beings cannot synthesize AA, and need to ingest it by means of meals and others. 
Therefore, antioxidative capacity was assessed in terms of elimination of superoxide anions 
and 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical. As compared with edaravone, AA is 
effective in elimination of superoxide and a stable synthetic radical, DPPH by a factor of 40 
and 1.8, respectively (Table 1). Thereafter, the cerebroprotective effect of oral two-week AA 
administration against ischemia/reperfusion was assessed. Infarcts were observed in cerebral 
striate and cortical matter in the non-DM rats group with ischemia/reperfusion receiving 
water alone (27.8% ± 4.2), but considerably reduced in the AA group at a dose of 100 mg/kg 
(16.5% ± 7.7). Infarcts were greater in the DM rats receiving water than in the non-DM 
counterparts by a factor of approximately 2.4 (65.6 ± 7.5 vs. 27.8% ± 4.2), affecting thalamus 
and whole gray matter. By contrast, in the AA-administered group, infarcts were present in 
confined regions of gray matter and thalamus (23.0% ± 9.9). The two-week AA 
administration mitigate considerably brain injury in both non-DM and DM rats (Figure 9, 
revised from reference [21]). 
 
Table 1. Scavenging effect of the free radical 
 
Sample Superoxide anion radical 
scavenger IC50 (mg/mL) 
DPPH radical scavenger 
EC50 (mg/mL) 
MAK 1.059 0.327 
edaravone 1.246 0.007 
ascorbic acid (AA) 0.039 0.004 
vitamin E 47.616 0.114 
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Figure 9. Effects of antioxidant on infarction induced by cerebral ischemia in rats. 
Representative data of TTC staining from the rats of the non-DM with sham operation 
group, distilled water administered (H2O) or AA or MAK supplemented non-DM or DM 
group with MCAO with reperfusion (MCAO/Re). AA (100 mg/kg body weight) or MAK (1 
g/kg body weight) or water was administrated once daily for 2 weeks by per os (p.o.). Scale 
bar = 5 mm. The data are presented as mean ± S.D. (n = 6-10). 
a
P < 0.05 vs. non-DM (H2O + 
MCAO/Re), 
b
P < 0.01 vs. DM ( H2O + MCAO/Re). 
In addition, in order to determine the protective efficacy of AA, the magnitude of 
oxidative stress and activity of antioxidative enzymes in those rats were assessed. The 
magnitude of oxidative stress in the DM rats was twice as high as in the non-DM rats (252.8 
± 32.9 U.CARR vs. 131.0 ± 7.0 U.CARR), whereas the magnitude was reduced in the DM 
rats receiving oral AA to the level of the non-DM rat group (137.3 ± 32.1 U.CARR). 
Antioxidative capacity was reduced in the DM rat group as compared with that in the non-
DM rat group receiving water by a factor of approximately 1.3 (1475.7 ± 67.1 U.CARR vs. 
1875.4 ± 156.1 U.CARR). 
The evidence indicates that the DM group was exposed to increased oxidative stress, 
while the antioxidative capacity was reduced. By contrast, in the AA-administered rat group, 
there was no significant variation of antioxidative capacity (1454.7 ± 101.9 U.CARR) [21]. In 
addition, the lipid peroxide-content of cerebral tissue was significantly elevated in the DM rat 
group as compared with in the non-DM rat group by a factor of 1.3 to 2.0, while the content 
was reduced significantly in the AA-administered DM rat group. The activities of cerebral 
SOD, CAT, and GPx were significantly reduced in the brain. Those results suggest that 
antioxidative enzymatic activity is reduced, leading to reduced antioxidative capacity with 
increased oxidative stress in the DM brain tissue. However, when AA was administered, 
enzymatic activity was not reduced, without difference with that of the non-DM rat group. 
Taking these findings together, antioxidative enzymatic activity is often reduced but AA 
retains the activity similar to that of nondiabetic level, inhibiting significantly lipid peroxide 
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formation in the brain. In conclusion, the maintenance of antioxidative enzymatic activity 
may play a role in eliminating excessively induced oxidative stress in ischemic brain injury 
among diabetic rats. 
As AA-administration had cerebroprotective effect in both non-DM and DM rat groups, 
its mechanism was assessed histopathologically. Superoxide production was increased in 
cortical penumbra in the DM rat group as compared with in the non-DM rat group by a factor 
of approximately 1.8 at baseline, which was suppressed to the level of the non-DM rat group. 
Cerebral superoxide production was increased with ischemia/reperfusion in the both groups, 
though greater in the DM rat group, which was suppressed with AA-administration. As 
inflammation plays an important role in the development of ischemic cerebral injury, the 
expression of related cytokines was assessed. TNF-α and IL-1β were intensively expressed at 
baseline, and the AA-administration significantly inhibited that expression. In addition, AA 
reduced considerably both of those increasingly expressed cytokines after 
ischemia/reperfusion.  
AA crosses BBB through two sorts of transporters, which is controlled by two 
mechanisms. One is sodium-coupled ascorbic acid transporter 2 (SVCT2) expressed in the 
choroid plexus and neurons, which transports reduced form of AA. Evidence suggests that the 
SVCT2 expression is intensified with ischemia/reperfusion, stimulating transfer of AA into 
the brain [83]. AA transfer is believed to be conducted by SVCT1. The other is glucose 
transporter 1 (GLUT1) expressed in BBB and neurons, which is involved in transport of 
dehydroascorbic acid (DHA), i.e., oxidized form of AA, in addition to glucose. GLUT1 
expression is reduced by a hypoxia-induced transcription factor, hypoxia inducible factor 
(HIF) [84]. Thus, both transporters are closely associated with ischemia, but the expression in 
a diabetic state is poorly understood. Therefore, genetic expression of SVCT2 and GLUT1 
was assessed. There was no difference in the SVCT2 expression at baseline between the non-
DM and DM groups even after AA-administration. However, after the ischemia/reperfusion 
procedure, the SVCT1 expression was increased despite the AA-administration in the non-
DM rat group, while not increased in the DM rat group and increased only at the AA-
administration. The GLUT1 expression was marginally reduced at baseline in the DM rat 
group as compared with in the non-DM rat group, but was increased with AA by a factor of 2 
in the both rat groups. The GLUT1 expression was profoundly intensified immediately after 
ischemia/reperfusion in both of the non-DM and DM rat group, on which AA had no effect 
[85].  
Other studies reported that AA and glutathione (GSH) is depleted in the cerebral tissue 
early in ischemia [86, 87], indicating the importance of AA-supply for the protection against 
excessive ROS caused by mitochondrial dysfunction. The evidence is supported by previous 
studies that diabetic hyperglycemia inhibited the GLUT1 expression in BBB through 
competitive inhibition by D-glucose [88]. Moreover, because Seno et al. used human 
umbilical vein-endothelium to reveal that INF-α and IL-1β suppress SCVT2 and affect 
transport of AA [89], inflammation may be closely involved in decreased expression of 
SVCT2. With regard to the levels of AA in plasma and cerebral tissue, the plasma level 
decreased after the sham-procure and the ischemia/reperfusion procedure in the DM rat 
group; and was similar to that in the non-diabetic state in the AA-administered rat group. In 
the cerebral tissue, the AA level was increased with the sham procedure in the non-DM AA-
administered rat group and reduced with the ischemia/reperfusion in both of non-DM and DM 
rat groups, whereas the AA level was similar to that in the sham group, in the AA-
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administered rat group. Given together, in the diabetic state, the SVCT expression is not 
elevated after ischemia/reperfusion, suggesting the AA depletion in the circulation because of 
oxidative stress; and the expression of GLUT1 which is involved in the transfer of oxidative 
AA is reduced at baseline. Those two factors may be associated with worsened cerebral injury. 
By contrast, the AA-administration in DM-rats improved the transporter expression to similar 
level of that of the non-DM rat group, suggesting increased AA-transfer to the brain.  
In conclusion, increased AA-transfer suppressed excessive ROS production after cerebral 
ischemia/reperfusion and the inhibition of lipid peroxide production may lead to 
cerebroprotection.  
 
 
3.2. Cerebroprotective Effect of Water-soluble Extract from Culture 
Medium of Ganoderma lucidum Mycelia (MAK) 
 
MAK is produced according to the below-mentioned procedures: hyphal bodies of Reishi 
mushroom of Ganoderma lucidum are inoculated to solid medium including bagasse and rice 
bran; and the whole medium is hot-water-extracted, sprayed, and dried with whole medium 
immediately before fruit body formation (Figure 10).  
The mushroom spores were germinated and cultured in liquid medium. The resulting 
Ganoderma lucidum mycelia pellet was injected into solid medium which was composed of 
bagasse and defatted rice bran (8:1, w/w). The medium was disrupted before the formation of 
fruit bodies (4 months). The disrupted material was incubated in water at 40-60°C for 60 hr to 
promote autolysis of the mycelia and partial digestion of the culture medium with mycelial 
enzymes. The digest was then extracted with water at 60°C. The extract was aseptically 
filtered and lyophilized. The resulting pale-brownish powder was designated MAK. 
 
 
Figure 10. Preparation of a water-soluble extract from culture medium of Ganoderma lucidum mycelia 
(MAK). 
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MAK has been used to maintain health among consumers for roughly two decades as a 
revitalizing healthfood product and nutrition supplement. Reishi mushroom also has long 
been used as a traditional medicine for revitalization and longevity, whose hyphal body or the 
constituents is reported to have various physiological activities including antihyperglycemic 
[90], immunomodulating [91], antineoplastic [92], antiviral [93], cholesterol-lowering [94], 
and antioxidative effects [95]. As MAK also contains solid medium-degradation products 
including water-soluble lignin caused by the hyphal bodies and hyphal autodigestion in 
addition to hyphal body components, its activity may differ from that of Reishi mushroom. 
The activities that have been reported include antihyperglycemic [96-99], immunostimulating 
[100], antineoplastic [101], antidepressive-like [102], and antihypertensive effects [103]. 
Moreover we revealed that oral MAK could alleviate ischemic cerebral injury [79, 103], and 
address, in this chapter, how MAK protects the brain. 
Initially, antioxidative capacity was assessed in terms of the elimination of superoxide 
anions and DPPH radicals. Although the DPPH radical elimination of MAK was inferior to 
that of AA, the superoxide anion elimination was similar to that of edaravone (Table 1). The 
cerebroprotective effect of MAK after two-week oral administration was also assessed. The 
infarct size was reduced (12.5% ± 4.9) in the MAK group at a dose of 1 g/kg body weight, 
which is greater than effect expected from AA, as compared with that of the water-
administered non-DM rat group (27.8% ± 4.2) after the ischemia/reperfusion. By contrast, 
although the infarct size was 65.6 ± 7.5% in the water-administered DM rat group, the size 
was profoundly reduced at 17.8% ± 11.2 (Figure 9, revised from reference [8]). Therefore, the 
mechanism of cerebroprotective effect of MAK was assessed. The magnitude of oxidative 
stress in the DM rats was approximately twice as high as in the non-DM rat group (252.8 ± 
32.9 U.CARR vs. 131.0 ± 7.0 U.CARR). By contrast, MAK had superior effect to AA at 
109.3 ± 15.1 U.CARR in the DM rat group. Moreover, as compared with no treatment, MAK 
administration reduced the stress at 84.3 ± 2.6 U.CARR. The evidence suggests that MAK 
has an intensive in vivo antioxidative property. By contrast, when water was administered, 
antioxidative capacity was significantly lower in the DM rat group at 1649.0 ± 101.2 μmol/L 
than in the non-DM rat group at 1475.7 ± 67.1 μmol/L, whereas MAK marginally reversed 
antioxidative capacity at 1649.0 ± 101.2 μmol/L in the DM rat group. In the MAK-
administered group, the intracerebral content of lipid peroxide was reduced, and the activities 
of SOD, CAT and GPx, which were low in the brain of the DM rat group, were 
enhanced/suppressed whereas, in the non-DM MAK rat group, the CAT activity was 
enhanced in the cerebral gray matter and cerebellum. Then, intracerebral superoxide 
production was evaluated with the use of the dihydroethidium (DHE) stain after 
ischemia/reperfusion: although the sham DM rat group showed a two-fold increase of 
superoxide, MAK administration reduced the level to that of the non-DM rat group. It was 
revealed that MAK considerably reduces the increase of superoxide after 
ischemia/reperfusion, indicating that chronic oxidative stress in the diabetic state was 
mitigated and involved in the elimination of excessive oxidative stress in ischemic brain 
injury. As discussed here, oxidative stress-associated inflammation is closely involved in the 
deterioration of ischemic brain injury. Thus, the management of inflammation may be 
important in inhibiting cell death. We evaluated the effect of MAK on ischemia/reperfusion-
induced cerebral apoptosis with the use of terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labeling (TUNEL) staining, and the expression of proinflammatory factors 
with the use of immunohistological method [79]. The number of TUNEL-positive cells in 
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cerebral penumbra in the DM rat group, as compared with in the non-DM rat group, 
significantly started to increase 3 hr after reperfusion, whereas the positive cell-number was 
significantly reduced in the non-DM and DM MAK-administered rat groups. These results 
indicate that MAK mitigates ischemia/reperfusion-induced inflammatory processes, and 
inhibits cell death, exerting a cerebroprotective effect [79].  
As discussed above, an explanation about deterioration of ischemic brain injury in DM 
rats is that variation in intracellular localization of HMGB1 occurs substantially, i.e., a lot of 
intranuclear HMGB1 in neurons is translocated into the cytoplasm and subsequently released 
into the extracellular space, inducing profound inflammation and cell death in surrounding 
tissue (Figure 7). In addition, MAK is believed to inhibit necrosis as well as apoptosis of 
cerebral neurons. Therefore, in order to determine the association of the cerebroprotective 
effect of MAK with the intracellular behavior of HMGB1, the effect of MAK on HMGB1 
behavior induced by various stimulations in cultured neuron-like pheochromocytoma cell line 
(PC12 cells) was assessed. PC12 cells were incubated with MAK of 1 μg/mL and 100 μg/mL, 
and exposed to biosimilar oxidative stress of H2O2 for 6 hr. Thereafter, intracellular ROS 
production was measured. ROS production was suppressed dependent of the MAK 
concentration. Thus, the finding that MAK inhibits oxidation of cerebral tissue in DM rats 
and lowers lipid peroxide content indicates that MAK may inhibit intraocular ROS 
production. Then, the effect of MAK in intracellular HMGB1 behavior was assessed. The 
translocation of intranuclear HMGB1 into cytoplasm and its extracellular release occurred in 
biosimilar oxidative stress H2O2-exposed cells, but the release was suppressed in the MAK-
pretreated cells. Furthermore, the translocation and release of HMGB1 similarly occurred in 
cells pretreated with TNF-α and recombinant HMGB1 (rHMGB1), which MAK suppressed 
(unpublished data). These results suggest that MAK could affect the initiation of 
inflammation due to oxidative stress efficiently, but not in TNF-α and HMGB1, which are 
precedingly released in the advanced inflammatory process after ischemic injury: i.e., MAK 
may inhibit intracellular ROS production and HMGB1 release in response to oxidative stress. 
MAK may exert antioxidative activity in the brain after crossing the BBB through 
Ganoderma lucidum hyphal body-derived constituents including proteoglycans and 
terpenoids as well as hyphal body-degraded solid medium constituents including soluble 
lignin and hyphal autodigestion products, but further studies are required to investigate that 
activity. Thus, the cerebroprotective effect of MAK that the present study revealed could be 
alleviated via HMGB1, but other factors may be involved. A recent study reported that, in an 
experimental hypoxic cerebral ischemia-animal model of mice with type 2 diabetes (KK-A
y
), 
MAK ingestion inhibited programmed cell death, necroptosis, extorting a cerebroprotective 
effect [104]. Therefore, in-depth investigation is required to elucidate the mechanisms.  
 
 
CONCLUSION 
 
Diabetes raises the oxidative stress of the whole body, increases the lipid peroxides of the 
brain. In addition, a diabetic state induces pro-inflammatory cytokines in the brain, 
conceivably via hyperglycemia and/or oxidative stress, accelerating intracellular translocation 
and the release of HMGB1 from neuronal cells after ischemic injury. The early release of 
HMGB1 and the promoting of inflammatory response may be involved in the aggravation of 
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neuronal damage caused by transient cerebral ischemia in diabetes. Therefore, it is important 
to inhibit the cytokines and HMGB1 released in response to ischemia during the treatment of 
post-ischemic injury in diabetic patients. In conclusion, MAK treatment inhibits the apoptotic 
and release of HMGB1 and attenuates the exacerbation of cerebral injury and neurological 
deficits in the diabetic state. These phenomena could be attributed to the antioxidant activity 
and anti-inflammatory effects of MAK. 
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